In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Chelsie Derman is an associate editor for HCPLive. She covers a range of topics within medicine and healthcare, focusing on areas such as psychiatry, sleep medicine, geriatrics, and allergies, while also exploring themes related to mental health care and pharmaceuticals. Chelsie's work has been featured in Contemporary Pediatrics, AJMC - The American Journal of Managed Care, Drug Topics, Contemporary OB/GYN, NewsBreak, Cliggott Publishing Co, HCP Live, and RamaOnHealthcare.